Panoramic Capital LLC bought a new stake in NeurAxis, Inc. (NASDAQ:NRXS – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 115,000 shares of the company’s stock, valued at approximately $841,000.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. AIGH Capital Management LLC purchased a new stake in NeurAxis during the 2nd quarter worth about $3,801,000. Rosalind Advisors Inc. acquired a new stake in shares of NeurAxis during the 4th quarter worth about $1,299,000. Money Concepts Capital Corp raised its position in shares of NeurAxis by 566.6% during the 4th quarter. Money Concepts Capital Corp now owns 222,605 shares of the company’s stock worth $1,011,000 after acquiring an additional 189,210 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in NeurAxis during the first quarter worth approximately $569,000. Finally, BlackRock Inc. purchased a new stake in NeurAxis during the second quarter worth approximately $429,000. 11.77% of the stock is currently owned by institutional investors and hedge funds.
NeurAxis Stock Down 1.3%
Shares of NRXS opened at $5.96 on Thursday. The stock has a 50 day moving average price of $6.75 and a 200 day moving average price of $6.80. The company has a market capitalization of $74.85 million, a price-to-earnings ratio of -3.24 and a beta of 1.49. NeurAxis, Inc. has a 52-week low of $2.21 and a 52-week high of $9.33.
NeurAxis Profile
NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.
NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.
Read More
- Five stocks we like better than NeurAxis
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding NRXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeurAxis, Inc. (NASDAQ:NRXS – Free Report).
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.
